Found 6 matching trials
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer PHASE1 The PI3K (phosphoinositol 3-Kinase) inhibitor Copanlisib and the MEK (mitog...
Show More Location
Multiple Locations
Learn More & Join Trial
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) PHASE2 This is a study to investigate the potential clinical benefit of refametini...
Show More Location
Multiple Locations
Learn More & Join Trial
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) PHASE2 This is a study to investigate the potential clinical benefit of refametini...
Show More Location
Multiple Locations
Learn More & Join Trial
BAY86-9766 Plus Gemcitabine Phase I Study in Asian PHASE1 This is an open-label, uncontrolled, Phase Ib study designed to evaluate th...
Show More Location
Multiple Locations
Learn More & Join Trial
Effect of Ketoconazole on the Pharmacokinetics of Refametinib PHASE1 The purpose of this study is to see if there is a difference between the wa...
Show More Location
Multiple Locations
Learn More & Join Trial
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer PHASE1 Phase I: Determine the maximum tolerated dose of combination of Regorafenib...
Show More Location
Multiple Locations
Learn More & Join Trial